Mabion S.A. (WSE: MAB)

Poland flag Poland · Delayed Price · Currency is PLN
9.63
+0.23 (2.45%)
Jan 20, 2025, 1:11 PM CET
-49.32%
Market Cap 153.22M
Revenue (ttm) 110.79M
Net Income (ttm) 10.24M
Shares Out 16.16M
EPS (ttm) 0.63
PE Ratio 15.05
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 15,092
Average Volume 57,828
Open 9.50
Previous Close 9.40
Day's Range 9.46 - 9.67
52-Week Range 8.38 - 20.45
Beta 1.13
RSI 42.82
Earnings Date Apr 17, 2025

About Mabion

Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. Mabion S.A. was founded in 2007 and is based in Konstantynów Lódzki, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 247
Stock Exchange Warsaw Stock Exchange
Ticker Symbol MAB
Full Company Profile

Financial Performance

In 2023, Mabion's revenue was 151.68 million, a decrease of -7.50% compared to the previous year's 163.98 million. Earnings were 41.27 million, an increase of 77.94%.

Financial Statements

News

There is no news available yet.